Share Price After Award Decision, page-131

TW - I don't understand why you take the stance you do as a shareholder. Still, you have have as much right as anyone to comment so I will focus on what you write rather than why. The series of links below show publicly available information about how the relevant patent applications were filed, changed and granted. The is an indication of late stage clinical development of the TPM^(R) Daptomycin back in 2015. You say: Not a viable product? Costs awarded against POH?  Management; The Board and Corrs knew a lot more than what we see here before proceeding to arbitration.

https://patents.google.com/patent/WO2011094814A1/en - World wide TPM patent

https://patents.google.com/patent/US20150216928A1/en - US patent not granted  

https://patents.google.com/patent/US20150216928A1/en - EU patent granted 

https://adisinsight.springer.com/drugs/800040371 - Indication of late stage clinical development